Table 2 Difference of GSI quantitative parameters between glioma recurrence and treatment-related changes
GSI quantitative parameters | glioma recurrence | treatment related changes | P Value |
|---|---|---|---|
Precontrast λHU | −0.007(− 0.477, 0.494) | −0.064(− 0.619, 0.310) | 0.859 |
Precontrast Zeff | 7.545 (7.353, 7.745) | 7.520 (7.295, 7.653) | 0.723 |
Precontrast Zeff-N | 1.007 (0.996, 1.012) | 1.005 (0.997, 1.012) | 0.965 |
Precontrast IC | −0.108(−2.598, 2.649) | −0.375(− 3.33, 1.428) | 0.790 |
Precontrast ICN | 0.733 (0.509, 1.102) | 0.969 (0.504, 1.086) | 0.723 |
Venous phase λHU | 1.426 ± 0.762 | 0.314 ± 0.373 | < 0.001 |
Venous phase Zeff | 8.034 ± 0.238 | 7.671 ± 0.151 | < 0.001 |
Venous phase Zeff-N | 1.058 ± 0.020 | 1.013 ± 0.024 | < 0.001 |
Venous phase IC | 7.319 ± 3.967 | 1.703 ± 2.049 | < 0.001 |
Venous phase ICN | 0.636(−2.140, 3.514) | 0.827(− 0634, 1.740) | 0.832 |